Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shanghai Fosun Omni Pharma Execs On The Market For Inhalation Products In China: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a joint venture between two former principal R&D leaders from Ivax/Teva and Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and Chief Operating Officer Shaochuan Zeng, the former leaders from Ivax/Teva, spoke with PharmAsia News' Shanghai bureau about their operation and the market for inhalation products in China.

You may also be interested in...



China’s Fosun Pharma Targets $650 Million IPO With Prudential Insurance As Cornerstone Investor

China’s largest non-state-owned pharma company Fosun Pharma commenced an initial global offering in Hong Kong, and nearly half of the money raised will be used for M&A. But the $650 million expected to be raised is much smaller than the rumored $800 million.

China’s Fosun Pharma Targets $650 Million IPO With Prudential Insurance As Cornerstone Investor

China’s largest non-state-owned pharma company Fosun Pharma commenced an initial global offering in Hong Kong, and nearly half of the money raised will be used for M&A. But the $650 million expected to be raised is much smaller than the rumored $800 million.

China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva

SHANGHAI - China's largest private integrated healthcare company Shanghai Fosun Pharmaceutical Co. Ltd. will focus on gaining more market share in China with its branded generic business and branded traditional Chinese medicines, the company said during China's first ever Biotechnology Industry Organization conference held in Shanghai

Related Content

UsernamePublicRestriction

Register

SC069757

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel